Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects

Journal of Clinical Pharmacology
Jules I SchwartzJohn A Wagner

Abstract

We determined cyclo-oxygenase-1 and cyclo-oxygenase-2 inhibition in healthy middle-aged subjects (41-65 years) randomly assigned to four 7-day treatment sequences of etoricoxib 90 mg every day, celecoxib 200 mg twice a day, diclofenac 75 mg twice a day, or placebo in a double-blind, randomized, 4-period crossover study. Maximum inhibition of thromboxane B(2) (cyclo-oxygenase-1 activity) in clotting whole blood on day 7 (0-24 hours postdose) was the primary endpoint. Inhibition of lipopolysaccharide-induced prostaglandin E(2) in whole blood (cyclo-oxygenase-2 activity) was assessed on day 7 (0-24 hours postdose) as a secondary endpoint. Diclofenac had significantly greater maximum inhibition of thromboxane B(2) versus each comparator (P < .001); placebo 2.4% (95% confidence interval: -8.7% to 12.3%), diclofenac 92.2% (91.4% to 92.9%), etoricoxib 15.5% (6.6% to 23.5%), and celecoxib 20.2% (11.5% to 28.1%). Prostaglandin E(2) synthesis was inhibited with a rank order of potency of diclofenac > etoricoxib > celecoxib. In summary, at doses commonly used in rheumatoid arthritis, diclofenac significantly inhibits both cyclo-oxygenase-1 and cyclo-oxygenase-2, whereas etoricoxib and celecoxib significantly inhibit cyclo-oxygenase-2 and ...Continue Reading

References

Sep 15, 1987·Thrombosis Research·F Catella, G A FitzGerald
Feb 1, 1996·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·C BrideauC C Chan
Oct 7, 1997·Clinical Pharmacokinetics·N M Davies, K E Anderson
Jan 6, 1999·Proceedings of the National Academy of Sciences of the United States of America·B F McAdamG A FitzGerald
Jun 23, 1999·Proceedings of the National Academy of Sciences of the United States of America·T D WarnerJ R Vane
Oct 9, 1999·The American Journal of Pathology·U SchönbeckP Libby
Oct 29, 2000·Lancet·J R Vane, T D Warner
Nov 23, 2000·The New England Journal of Medicine·C BombardierUNKNOWN VIGOR Study Group
Dec 26, 2001·The New England Journal of Medicine·F Catella-LawsonG A FitzGerald
Apr 20, 2002·Science·Yan ChengGarret A FitzGerald
May 30, 2002·BMC Family Practice·Eduardo CollantesUNKNOWN Etoricoxib Rheumatoid Arthritis Study Group
Sep 16, 2003·Journal of Clinical Pharmacology·Joanne BurkeScott A Waldman
Apr 20, 2005·Journal of the American College of Cardiology·Marta L CaponePaola Patrignani
Jan 6, 2006·The Journal of Clinical Investigation·Tilo GrosserGarret A FitzGerald
Feb 24, 2006·The American Journal of Medicine·Gurkirpal SinghUNKNOWN SUCCESS-I Investigators
Apr 14, 2006·Basic & Clinical Pharmacology & Toxicology·Sonia Hernández-DíazLuis A García Rodríguez
Jun 21, 2006·Journal of Cardiovascular Pharmacology·Loren Laine
Sep 1, 2006·The New England Journal of Medicine·Monica M BertagnolliUNKNOWN APC Study Investigators
Sep 6, 2006·Clinical Pharmacology and Therapeutics·Giulia RendaPaola Patrignani
Sep 30, 2006·Journal of Thrombosis and Thrombolysis·Walter S SchroederPritesh J Gandhi
Nov 8, 2006·Gastroenterology·John A BaronUNKNOWN APPROVe Trial Investigators
Nov 23, 2006·Lancet·Luis Alberto García Rodríguez, Paola Patrignani
Jan 26, 2007·The New England Journal of Medicine·Bruce M Psaty, Noel S Weiss
Feb 6, 2007·Trends in Pharmacological Sciences·Nicholas A Flavahan

❮ Previous
Next ❯

Citations

Jan 7, 2010·Naunyn-Schmiedeberg's Archives of Pharmacology·Bertold RennerKay Brune
Jul 30, 2010·International Journal of Clinical Practice·B H McCarberg, C E Argoff
Jan 12, 2010·Annual Review of Medicine·Tilo GrosserGarret A Fitzgerald
Nov 7, 2012·Expert Opinion on Drug Metabolism & Toxicology·Rik J Lories
Sep 19, 2009·Trends in Pharmacological Sciences·James M RitterJohn B Warren
Jul 26, 2011·Journal of Pharmaceutical and Biomedical Analysis·Derek L ChappellOmar F Laterza
Aug 30, 2016·Seminars in Arthritis and Rheumatism·Choochai TeerawattananonWanruchada Katchamart
Nov 27, 2018·Current Medical Research and Opinion·K D RainsfordClarence Jones
Mar 13, 2010·The Journal of Maternal-fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·Cennet RagbetliMurat C Ragbetli
Nov 5, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Eva M SturmAkos Heinemann
Apr 11, 2019·Brazilian Dental Journal·Marcella Goetz MoroMarinella Holzhausen
Mar 3, 2021·Andrologia·Saleem Ali Banihani
Jul 20, 2021·Pharmacology Research & Perspectives·Christopher J EshLee Taylor

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.